In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.
He said that pharma companies are aware that US generic market is not a one-way street.
According to him new draft pharma policy will reduce risks like generalisation of market.
He said that it is tough to talk about timeline with regards to recovery in pharma space.
Cipla looks good due to no visible overhang, he said.
On DRL front, he said biggest risk stands on Dr Reddy's Laboratories from Duvvada perspective.Watch accompanying video for more details.